Ketamine Treatment Side Effects: What Could Be Causing Them

Why Ketamine Causes Side Effects in the First Place

Ketamine is a noncompetitive NMDA receptor antagonist that also interacts with opioid, monoaminergic, and cholinergic pathways. This broad receptor profile explains why side effects span multiple organ systems rather than clustering in one area. The drug's rapid onset (seconds for IV, minutes for intranasal) means effects appear quickly and, for most patients, resolve within hours as plasma levels decline 1.

A 2018 systematic review by Short et al. (N=60 studies, 899 participants) cataloged side effects across ketamine depression trials and found that 29 distinct adverse events were reported, with dissociation (61%), drowsiness (25%), and elevated blood pressure (22%) being the three most frequent 1. The S-enantiomer (esketamine) has roughly twice the binding affinity at NMDA receptors compared to racemic ketamine, which partly explains why FDA labeling for Spravato carries specific warnings about dissociation and sedation 2.

Not every side effect means something is wrong. Mild dissociation during a 40-minute IV infusion, for example, is pharmacologically expected and correlates with therapeutic response in some studies 3. The clinical question is whether your specific symptoms fall within the anticipated range or signal a need to adjust the protocol.

Dissociation and Perceptual Disturbances

Dissociation is the signature side effect of ketamine. It occurs because NMDA receptor blockade in the prefrontal cortex and hippocampus disrupts the normal integration of sensory input with self-awareness. Patients describe it as feeling detached from their body, perceiving time distortion, or experiencing visual changes.

In the Phase 3 TRANSFORM-2 trial (N=223) of esketamine for treatment-resistant depression, 61% of esketamine patients reported dissociation on the Clinician-Administered Dissociative States Scale, compared to 5% on placebo 4. Scores peaked at 40 minutes post-dose and returned to baseline by 1.5 hours in the vast majority of cases.

What makes this side effect clinically relevant is its relationship to dose and route. IV infusions at 0.5 mg/kg over 40 minutes produce moderate dissociation in most patients. Higher doses or faster infusion rates intensify the effect significantly. Dr. Gerard Sanacora, director of the Yale Depression Research Program, has noted: "The dissociative effects are dose-dependent, and careful titration can minimize them without sacrificing antidepressant efficacy" 5.

If dissociation is severe, persistent beyond 4 hours, or accompanied by paranoia, the infusion rate or dose likely needs adjustment. Patients with a personal or family history of psychotic disorders face higher risk, and most protocols exclude these individuals 6.

Cardiovascular Effects: Blood Pressure and Heart Rate Spikes

Ketamine stimulates the sympathetic nervous system by inhibiting norepinephrine reuptake at peripheral nerve terminals. This produces a transient rise in blood pressure and heart rate that typically peaks 15 to 40 minutes into an IV infusion and normalizes within 4 hours.

In Short et al.'s pooled analysis, 22.4% of participants across depression trials experienced blood pressure increases 1. The mean systolic rise was approximately 20 mmHg. A separate analysis of 205 ketamine infusions by Wan et al. (2015) found that the maximum mean arterial pressure occurred at 40 minutes and returned to pre-infusion levels by 120 minutes 7.

These elevations are rarely dangerous in patients with normal baseline cardiovascular status. The concern arises when patients have uncontrolled hypertension, aortic aneurysm, or recent stroke. The American Psychiatric Association's 2017 consensus statement on ketamine specifically recommends baseline blood pressure screening and continuous monitoring during infusions, noting that "patients with uncontrolled hypertension should not receive ketamine until blood pressure is adequately managed" 5.

Tachycardia is less commonly reported than blood pressure changes but follows the same mechanism. Heart rate increases of 10-20 beats per minute are typical. Clinics using beta-blocker pretreatment (such as labetalol) can blunt both cardiovascular responses when indicated 7.

Nausea and Vomiting

Nausea affects 15 to 30% of patients receiving ketamine infusions 1. The mechanism involves two pathways: direct stimulation of the chemoreceptor trigger zone in the area postrema and vestibular disturbance linked to ketamine's effects on spatial processing.

A 2020 retrospective analysis by Acevedo-Diaz et al. at the National Institute of Mental Health (N=163 infusions across 39 patients) found that nausea occurred in 25.2% of infusions and vomiting in 6.1% 8. Pretreatment with ondansetron (4 mg IV) reduced nausea incidence to under 10% in subsequent studies at the same center.

Several factors increase nausea risk. Fasting for fewer than 4 hours before infusion correlates with higher rates. The intranasal route may provoke less nausea than IV delivery because peak plasma concentrations are lower and rise more gradually. Patients who report motion sickness are disproportionately affected, supporting the vestibular component of the mechanism 8.

If nausea persists across multiple treatment sessions despite ondansetron, switching from IV to sublingual or intranasal formulations, reducing the infusion rate, or adding a scopolamine patch are standard clinical adjustments.

Urinary Tract Symptoms and Ketamine Cystitis

Ketamine cystitis represents the most serious organ-specific toxicity associated with repeated ketamine exposure. It presents as urinary frequency, urgency, dysuria, suprapubic pain, and in advanced cases, a contracted bladder with severely reduced capacity.

This condition was first described in recreational users consuming grams per day, but case reports have emerged in clinical patients receiving repeated therapeutic doses. A 2007 case series by Shahani et al. in the journal Urology documented severe bladder damage in 9 patients using street ketamine, with cystoscopy showing ulcerative changes and bladder capacities as low as 100 mL 9.

The mechanism appears to involve direct toxicity of ketamine and its metabolite norketamine on the urothelium. Animal models show dose-dependent urothelial inflammation, submucosal edema, and fibrosis 10.

At typical clinical doses (0.5 mg/kg IV, administered once or twice weekly), urinary toxicity is rare. A 2023 review in the American Journal of Psychiatry examined the safety of repeated ketamine infusions in psychiatric populations and concluded that "lower-dose, intermittent dosing regimens used in clinical settings carry substantially lower urological risk than the chronic, high-dose patterns seen in recreational use" 11. Patients receiving maintenance ketamine should report any new urinary symptoms promptly. Urinalysis and bladder diaries are reasonable monitoring tools for patients on extended treatment protocols.

Hepatic Effects

Elevated liver enzymes have been documented in patients receiving repeated ketamine infusions. The mechanism involves CYP3A4 and CYP2B6 metabolism generating reactive intermediates that may cause hepatocellular injury in susceptible individuals.

A retrospective chart review by Schwenk et al. (2018) found that 3 of 20 patients (15%) receiving prolonged ketamine infusions for chronic pain developed transaminase elevations exceeding three times the upper limit of normal 12. These elevations normalized after ketamine was discontinued, suggesting a reversible, dose-dependent process rather than permanent liver damage.

Baseline and periodic liver function testing is warranted for patients receiving ongoing ketamine treatment. The Endocrine Society and other groups have not issued specific hepatic monitoring guidelines for ketamine, but pain medicine consensus recommendations suggest checking ALT and AST at baseline, monthly for the first three months, then quarterly 12.

Patients using other hepatotoxic medications (acetaminophen at high doses, certain anticonvulsants, or chronic alcohol) face compounded risk and require closer monitoring.

Psychiatric and Cognitive Side Effects

Acute psychiatric effects during ketamine infusion include anxiety, euphoria, and transient thought disorganization. These resolve within hours. The more clinically significant concern is whether repeated ketamine exposure produces lasting cognitive impairment.

Evidence from recreational ketamine users shows dose-dependent deficits in working memory, episodic memory, and attention. Morgan et al. (2010) followed 150 recreational users and 100 controls over 12 months and found that frequent users (defined as more than 4 days per week) showed significant declines on tests of spatial working memory and pattern recognition 13.

Therapeutic doses appear to carry substantially lower cognitive risk. In the SUSTAIN-1 trial of esketamine (N=297), no significant cognitive decline was observed over 48 weeks of intermittent dosing as measured by the Cogstate battery 14.

Dr. Carlos Zarate Jr., chief of the Section on the Neurobiology and Treatment of Mood Disorders at the National Institute of Mental Health, has stated: "At the doses and frequencies used in clinical treatment, the cognitive effects of ketamine appear to be transient and do not accumulate in the way seen with chronic recreational abuse" 3.

Abuse potential is a separate concern. Ketamine is a Schedule III controlled substance. The esketamine REMS program requires in-office administration and 2-hour post-dose observation specifically to mitigate diversion risk. Patients with active substance use disorders require careful risk-benefit assessment before starting any ketamine protocol 2.

Drug Interactions That Amplify Side Effects

Ketamine side effects can intensify when the drug interacts with other medications. Benzodiazepines reduce dissociation but may also blunt the antidepressant response; a post-hoc analysis of TRANSFORM trials found that benzodiazepine users had a smaller treatment effect 4.

CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice) slow ketamine metabolism and raise plasma levels, potentially amplifying all side effects. CYP3A4 inducers (carbamazepine, rifampin) do the opposite and may reduce efficacy 15.

Combining ketamine with other sympathomimetics or MAO inhibitors increases cardiovascular risk. Lamotrigine has shown some ability to reduce dissociation without diminishing antidepressant effects in small studies, though this remains investigational 15.

Patients should provide a complete medication list before starting ketamine treatment. Even common substances like caffeine can augment the cardiovascular response.

When Side Effects Signal You Should Stop Treatment

Most ketamine side effects are transient and self-limiting. But certain presentations require immediate medical attention or treatment discontinuation.

Stop treatment and seek evaluation if you experience: blood pressure exceeding 180/120 mmHg during infusion, dissociation lasting beyond 6 hours, new-onset urinary frequency or pain, persistent vomiting unresponsive to antiemetics, or suicidal ideation that intensifies (rather than improves) after the session 5.

Yellowing of the skin or eyes, dark urine, or right upper quadrant abdominal pain suggest hepatic involvement and warrant immediate liver function testing. Any psychotic symptoms (command hallucinations, fixed delusions, loss of reality testing) constitute an absolute contraindication to further treatment 6.

Monitoring should occur at every treatment session. The FDA's esketamine labeling mandates blood pressure measurement before dosing and at 40, 60, 90, and 120 minutes post-dose, with medical intervention protocols for readings above 180/110 mmHg 2. Clinics administering IV racemic ketamine should follow equivalent or stricter protocols, even though racemic ketamine remains off-label for depression.